Sign In
Buy TLSA
$1.18
-0.180 (-13.24%)
At Close: Jun 03, 2026
Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
08:30am, Thursday, 13'th Nov 2025
BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies wi
Tiziana Life Sciences: Foralumab's Intranasal Push Is A Good Moonshot
09:43am, Friday, 31'st Oct 2025
Tiziana Life Sciences' Foralumab intranasal anti-CD3 targets the Treg–microglia axis. However, their intranasal delivery makes them unique and patient-friendly. Foralumab has a Phase 2 for SPMS, a P
Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
07:00am, Wednesday, 29'th Oct 2025
BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies wi
Tiziana Life Sciences to showcase drug candidate at Saudi innovation forum
08:47am, Tuesday, 30'th Sep 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Tuesday it has been invited to present at a major biotechnology conference in Riyadh, underscoring Saudi Arabia's push to position itself as a global hub f
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
08:30am, Tuesday, 30'th Sep 2025
BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.
Tiziana Life Sciences stock higher on inflammatory therapy plans
11:44am, Thursday, 25'th Sep 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares rose more than 10% in late morning trading on Thursday after the biotech company said it plans to advance development of TZLS-501, an antibody that
Tiziana to push ahead with second drug candidate in inflammation research
10:37am, Thursday, 25'th Sep 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Thursday it plans to advance development of TZLS-501, an antibody that blocks a key inflammatory pathway, at a time when big drugmakers are paying closer a
Tiziana to share trial design for nasal MS drug at global congress
09:16am, Wednesday, 24'th Sep 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) is set to highlight the design of its mid-stage trial for an experimental multiple sclerosis treatment at a leading international neurology conference this week
Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
08:30am, Wednesday, 24'th Sep 2025
BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.
Tiziana Life Sciences awarded DoD grant to advance intranasal therapy for spinal cord injury
09:24am, Monday, 15'th Sep 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has been awarded a US Department of Defense (DoD) research grant to advance its intranasal anti-CD3 therapy in traumatic spinal cord injury (S
Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury
08:00am, Monday, 15'th Sep 2025
BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
10:04am, Tuesday, 09'th Sep 2025
BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies w
Tiziana Life Sciences Announces Purchase of Shares by Chairman
08:30am, Friday, 05'th Sep 2025
BOSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies w
Tiziana Life Sciences doses first MSA patient in new trial – ICYMI
04:36pm, Friday, 15'th Aug 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi talked with Proactive about the company's latest milestone: dosing the first patient in its Phase 2a clinical trial targeting multiple system at
Tiziana Life Sciences doses first patient in Phase 2a MSA trial
09:44am, Thursday, 14'th Aug 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has enrolled and dosed the first participant in its Phase 2a clinical trial evaluating intranasal foralumab in patients with Multiple System A
